ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023
14 Julho 2023 - 8:37AM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for the treatment of renal and inflammatory diseases with
high unmet medical needs, announces that Stephen C. Glover,
Co-Founder, Chairman, Chief Executive Officer, and President, has
been invited to speak at the H.C. Wainwright 2nd Annual Kidney
Conference being held virtually on July 25, 2023. During the
presentation, Mr. Glover will highlight the unique mechanism of
action of Cholesterol Efflux Mediator™ VAR 200 and its potential
role in the treatment of kidney disease. He will also provide an
update on VAR 200’s development status.
Details regarding Mr. Glover’s Presentation follow:
Event: H.C. Wainwright 2nd
Annual Kidney ConferenceDate: Tuesday, July 25,
2023Time: 10:00 – 10:30 AM
EDTREGISTRATION: HCW Kidney
Conference
“We are pleased to have the opportunity to discuss the unique
mechanism of action of Cholesterol Efflux Mediator™ VAR 200 and its
potential role in the treatment of kidney disease at the H.C.
Wainwright 2nd Annual Kidney Conference,” stated Mr. Glover.
“Around 36 million people in the US have chronic kidney disease
which progresses over time leading to the need for dialysis and
kidney transplant, yet treatment options are limited. According to
the CDC, in 2020 nearly 558,000 people were on dialysis and nearly
250,000 were living with a kidney transplant. We commend H.C.
Wainwright for hosting this conference to address new kidney drugs
in development to help address this significant unmet medical
need.”
To learn more about ZyVersa and its differentiated product
pipeline, please schedule a one-on-one meeting with Mr. Glover
through the conference portal.
About Cholesterol Efflux
MediatorTM VAR 200
Cholesterol Efflux MediatorTM VAR 200
(2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready
drug in development to ameliorate renal lipid accumulation that
damages the kidneys’ filtration system, leading to kidney disease
progression. VAR 200 passively and actively removes excess lipids
from the kidney.
Preclinical studies with VAR 200 in animal models of FSGS,
Alport syndrome, and diabetic kidney disease demonstrate that
removal of excess cholesterol and lipids from kidney podocytes
protects against structural damage and reduces excretion of protein
in the urine (proteinuria).
The lead indication for VAR 200 is orphan kidney disease focal
segmental glomerulosclerosis (FSGS). VAR 200 has potential to treat
other glomerular diseases, including orphan Alport syndrome and
diabetic kidney disease.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 developed to
ameliorate renal lipid accumulation that damages the kidneys'
filtration system in patients with glomerular kidney diseases, and
Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation
associated with numerous CNS and other inflammatory diseases. For
more information, please visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR Contact:Karen CashmereChief
Commercial Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic
Advisors, Inc.Casey
McDonaldcmcdonald@tiberend.com646-577-8520
Dave Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024